Bruker

Bruker Corp. engages in the development, manufacture, and distribution of scientific instruments, and analytical and diagnostic solutions that enable customers to explore life and materials at microscopic, molecular, and cellular levels. It operates through the following segments: Bruker Scientific Instruments (BSI) Life Science, BSI Nano, and Bruker Energy and Supercon Technologies (BEST). The BSI Life Science segment includes enabling life science tools based on magnetic resonance technology. The BSI Nano segment offers x-ray instruments that use electromagnetic radiation with wavelengths to determine the characteristics of matter and the three-dimensional (3D) structure of molecules. The BEST segment consists of conducting materials, primarily metallic low temperature superconductors, for use in magnetic resonance imaging, nuclear magnetic resonance, fusion energy research, and other applications. The company was founded by Gunther Laukien in 1960 and is headquartered in Billerica, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Bruker reports robust 2022 performance, eyes growth amid challenges

Bruker's strong financial performance in 2022, driven by organic revenue growth and strategic investments, positions the company for continued success.
While facing supply chain challenges and geopolitical risks, Bruker remains optimistic about growth opportunities in proteomics and spatial biology.
Confidence in 2023 outlook is supported by strong bookings, backlog visibility, and expectations of solid organic growth in key markets.

Bruker reports strong Q1 earnings, eyes spatial biology markets

Bruker's Q1 2023 performance showcased robust revenue growth and margin improvement, with strong demand across key segments and regions.
While facing challenges like margin declines and supply chain constraints, the company is well-positioned to capitalize on opportunities in spatial biology and proteomics markets.
By focusing on innovation, capacity investments, and addressing backlog delays, Bruker aims to sustain growth momentum and meet future demand expectations.
Overall, Bruker's strategic initiatives and market positioning indicate a positive outlook for continued growth and market leadership in the analytical instruments industry.

Bruker reports strong Q2 earnings, eyes global growth opportunities

Bruker's Q2 2023 performance reflects strong revenue and EPS growth, driven by demand across key segments and regions. The company's focus on innovation and global expansion positions it well for future growth.
While facing challenges such as high lead times and supply chain issues, Bruker is proactively managing costs and investing in capacity to meet demand. Opportunities for organic growth and profitability through strategic investments and pricing trends are on the horizon.
Overall, Bruker's Q2 2023 earnings call highlights a resilient performance, strategic strengths in R&D and global presence, challenges in capacity and logistics, and opportunities for sustained growth and profitability.

Bruker reports strong Q3 earnings and eyes sustainable growth

Bruker's Q3 2023 performance reflects robust revenue and earnings growth, supported by strong organic growth and strategic acquisitions.
While facing challenges in biopharma investments and China trends, Bruker's strengths lie in its elevated backlog and growth opportunities in green tech and academic funding.
The company's focus on high-end Life Science tools in China and long-term growth prospects position it well for sustained success.
Overall, Bruker's performance in Q3 2023 showcases resilience and strategic positioning for future growth.

Bruker excels in Q4 2023, eyes accelerated growth and acquisitions

Bruker's strong Q4 2023 performance showcased robust revenue and EPS growth, though challenges like margin pressure and geopolitical risks persist. With a focus on strategic acquisitions and market opportunities, Bruker aims for continued growth and innovation.

Bruker boosts revenue guidance after Q1 growth, faces margin challenges

Bruker's Q1 2024 performance showed growth despite margin challenges, with increased revenue guidance for the year.
Strong geographic revenue growth in the Americas and Europe contrasted with a decline in Asia Pacific.
Strategic acquisitions and focus on organic growth present opportunities for Bruker in 2024.
Challenges include margin compression, dilution from integration, and lower organic growth due to order distortions.

Bruker reports robust Q2 earnings, eyes growth in key sectors

Bruker's strong Q2 performance and strategic acquisitions are driving growth in key areas like spatial biology and molecular diagnostics.
While facing margin challenges due to recent acquisitions, the company remains confident in achieving operational excellence and margin expansion.
Maintaining mid-single-digit organic revenue growth and focusing on operational efficiency position Bruker for continued success in the market.
The company's outlook remains positive with opportunities for growth through acquisitions and market demand for its innovative solutions.

Bruker reports strong Q3 earnings, eyes margin expansion in 2025

Bruker's Q3 '24 performance was strong, with revenue growth and margin improvements.
Challenges include weaker-than-expected demand in biopharma and China markets.
Anticipated opportunities lie in margin expansion and innovative solutions in 2025.
Focus on driving improvements in acquired businesses to drive growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Bruker Corp. engages in the business of developing, manufacturing, and distributing high-performance scientific instruments and analytical and diagnostic solutions that enable customers to explore life and materials at microscopic, molecular, and cellular levels. It operates through the following segments: Bruker Scientific Instruments (BSI) BioSpin, BSI Chemicals, Applied Markets, Life Science, In-Vitro Diagnostics, Detection (CALID), BSI Nano, and Bruker Energy and Supercon Technologies (BEST). The BSI BioSpin segment includes life science tools based on magnetic resonance technology. The BSI CALID segment focuses on life science mass spectrometry and ion mobility spectrometry solutions, analytical and process analysis instruments, and solutions based on infrared and Raman molecular spectroscopy technologies and radiological and nuclear detectors for chemical, biological, radiological, nuclear, and explosive detection. The BSI Nano segment offers advanced x-ray instruments, atomic force microscopy instrumentation, advanced fluorescence optical microscopy instruments, analytical tools for electron microscopes and x-ray metrology, defect-detection equipment for semiconductor process control, handheld, portable, and mobile x-ray fluorescence spectrometry instruments, spark optical emission spectroscopy systems, and chip cytometry products and services for targeted spatial proteomics, multi-omics services, and products and services for spatial genomics research. The BEST segment is involved in superconducting and non-superconducting materials and devices for use in renewable energy, energy infrastructure, healthcare, and big science research. The company was founded by Emil Bruker and Günther Laukien in 1960 and is headquartered in Billerica, MA.

Bruker's (BRKR) FluoroType SARS-CoV-2 varID Q assay is anticipated to provide reliable detection of the novel Omicron (B.1.1.529) variant of SARS-CoV-2.

Bruker (BRKR) Assay to Offer Reliable Omicron Variant Detection

NEHREN, Germany--(BUSINESS WIRE)---- $BRKR #BRKR--Bruker Corporation (Nasdaq: BRKR) today announced that its established CE-IVD marked FluoroType® SARS-CoV-2 varID Q real-time multiplexed PCR assay reliably detects all SARS-CoV-2 variants, and in addition is expected to also provide a clear indication of Omicron (B.1.1.529), recently declared a ‘variant of concern' by the WHO. FluoroType® SARS-CoV-2 varID Q is a multiplexed CE-IVD marked PCR assay for the detection and quantification of all major SARS-CoV-2 va

Bruker Expects its FluoroType® SARS-CoV-2 varID Q PCR Assay to Reliably Detect and Tentatively Differentiate Omicron (B.1.1.529) Variant

Bruker (BRKR) reported earnings 30 days ago. What's next for the stock?

Bruker (BRKR) Down 0.8% Since Last Earnings Report: Can It Rebound?

Investors are optimistic about Bruker's (BRKR) better-than-expected results and strong segmental performance.

Here's Why You Should Invest In Bruker (BRKR) Stock for Now

Cars.com

CNH Industrial NV

KAR Auction Services

Meredith

Raven Industries

NEW YORK, Nov. 24, 2021 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P MidCap 400 and S&P SmallCap 600 effective prior to the opening of trading on Thursday, December 2: Bruker BioSciences Corp. (NASD:BRKR) will replace KAR Auction Services Inc. (NYSE:KAR) in the S&P MidCap 400, and KAR Auction Services will replace Meredith Corp. (NYSE:MDP) in the S&P SmallCap 600. Meredith is being acquired in a two-step transaction that is expected to be completed on or about December 1.

Bruker BioSciences Set to Join S&P MidCap 400; Others to Join S&P SmallCap 600

GHENT, Belgium--(BUSINESS WIRE)--Bruker Corporation (Nasdaq: BRKR) today announced the acquisition of MOLECUBES NV, a dynamic innovator in benchtop preclinical nuclear molecular imaging (NMI) systems. This acquisition strengthens Bruker's position as a leading NMI solutions provider in preclinical and translational imaging research. The combination of Bruker's preclinical imaging products and global footprint with the modular benchtop CUBES™ systems of MOLECUBES will provide a broader NMI offer

Bruker Announces Acquisition of MOLECUBES NV

Talking about these three developments, Bruker (BRKR) notes that because of complex sample preparation protocols, the widespread adoption of proteomics has been limited.

Bruker (BRKR) Advances in Proteomics Workflow With New Pacts

BILLERICA, Mass.--(BUSINESS WIRE)--At the virtual 20th Human Proteome Organization World Congress, HUPO Reconnect 2021 (hupo2021.org) Bruker Corporation (Nasdaq: BRKR) announced major advances in collision cross section (CCS) enabled 4D proteomics workflows on the unique timsTOF multiomics platform. Dr. Gary Kruppa, Bruker's Vice President for Proteomics, stated: “Widespread adoption of proteomics has been limited by complex sample preparation protocols that were not easily automated. We are ex

Bruker Announces Collaborative Advances in CCS-Enabled 4D Proteomics Workflows at HUPO

BILLERICA, Mass.--(BUSINESS WIRE)--Bruker Corporation (Nasdaq: BRKR) today announced that its Board of Directors has approved payment of a quarterly cash dividend in the amount of $0.04 per share on the Company's common stock. The dividend will be paid on December 17, 2021 to stockholders of record as of December 1, 2021. In addition, the Board approved the Company's plan to increase its annual cash dividend from $0.16 to $0.20, payable quarterly beginning in March 2022, subject to quarterly Bo

Bruker Announces Fourth Quarter 2021 Dividend

BILLERICA, Mass.--(BUSINESS WIRE)--Bruker to participate in 2021 Jefferies London Healthcare Conference

Bruker Corporation to Participate in the 2021 Jefferies London Healthcare Conference

Bruker (BRKR) reports better-than-expected earnings and revenues for the third quarter of 2021 on geographical performance driving the top line.

Bruker (BRKR) Q3 Earnings Surpass Estimates, Margins Up

Bruker Corp's (NASDAQ: BRKR) Q3 revenues were $608.9 million, up 19.1 Y/Y (17.8% organically) and beating the Wall Street estimate of $574.17 million. The company saw a 1% positive effect on revenues from currency translation and a positive impact of less than 1% from acquisitions.

Bruker Clocks 19% Jump In Q3 Sales; Lifts FY21 Guidance

PHILADELPHIA--(BUSINESS WIRE)--At the 69th ASMS meeting in Philadelphia, Bruker Corporation (Nasdaq: BRKR) announced novel CCS-enabled 4D proteomics for major capability enhancements for timsTOF Pro 2, timsTOF fleX and timsTOF SCP mass spectrometers. Dr. Rohan Thakur, Bruker's EVP for Life Sciences Mass Spectrometry explained: “TIMScore developed by the Yates Lab at Scripps reduces peptide candidate ambiguity by evaluating predicted against experimental CCS, for forward and decoy/reverse peptid

Bruker Announces Major Advances in CCS-Enabled 4D Proteomics at ASMS

Bruker Corporation's (BRKR) CEO Frank Laukien on Q3 2021 Results - Earnings Call Transcript

Bruker (BRKR) delivered earnings and revenue surprises of 40.00% and 5.65%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Bruker (BRKR) Q3 Earnings and Revenues Beat Estimates

Bruker (NASDAQ:BRKR) reported its Q3 earnings results on Monday, November 1, 2021 at 04:00 PM. Here's what investors need to know about the announcement.

Bruker: Q3 Earnings Insights

BILLERICA, Mass.--(BUSINESS WIRE)--Bruker Reports Third Quarter 2021 Financial Results

Bruker Reports Third Quarter 2021 Financial Results

Alkermes

BioNTech SE

Heska

Inmode Ltd

Joint

Prothena

It looks like we're on the back end of the Covid pandemic, so it's a good time to look at healthcare stocks that have a big future. The post 7 A-Rated Healthcare Stocks to Buy for the Long Haul appeared first on InvestorPlace.

7 A-Rated Healthcare Stocks to Buy for the Long Haul

BILLERICA, Mass.--(BUSINESS WIRE)---- $BRKR #BRKR--Bruker Corporation (Nasdaq: BRKR) today announced it will report third quarter 2021 financial results on Monday, November 1, 2021, after the market closes. The Company will host a conference call and webcast at 4:30 p.m. Eastern Time to discuss the results and current business trends. To listen to the webcast, investors can go to https://ir.bruker.com and click on the “Q3 2021 Earnings Webcast” hyperlink in the “Events & Presentations” section. A slide pre

Bruker Announces Date and Time of Third Quarter 2021 Earnings Release and Webcast

The heavy selling pressure might have exhausted for Bruker (BRKR) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

After Plunging 14% in 4 Weeks, Here's Why the Trend Might Reverse for Bruker (BRKR)

BILLERICA, Mass.--(BUSINESS WIRE)---- $BRKR #BRKR--Bruker Corporation (Nasdaq: BRKR) today announced that it has received orders for two 1.1 GHz NMR Avance Neo systems from U.S. academic institutions funded by the National Science Foundation (NSF). NSF awarded the funds to establish the Network for Advanced NMR (NAN) linking three institutions including the University of Connecticut School of Medicine, the University of Georgia and University of Wisconsin–Madison. NAN is a novel consortium with the goal to est

NSF-Funded Network for Advanced NMR Orders Two 1.1 GHz NMR Systems to Advance Protein Structure and Dynamics Research

Bruker posted better-than-expected second quarter results, as the company is seeing a broad recovery across its academic, applied, clinical, and industrial end-markets. Project Accelerate 2.0 is the next iteration of an already-successful program to refocus the company's core technologies and capabilities on growth markets in life sciences and diagnostics.

Bruker's Renewed Focus On Growth Has Lit A Fire Under The Shares

The stock price of Bruker Corporation, a scientific instruments manufacturer, primarily for molecular and materials research, has seen a rise of around 12% over the last twenty-one trading days, and it is up a solid 123% over the last twelve-month period. The rally in BRKR stock over the recent.

Bruker Stock Is At An All-Time High But Will The Rally Continue?

Bruker (BRKR) Up 9.3% Since Last Earnings Report: Can It Continue?

BILLERICA, Mass.--(BUSINESS WIRE)--Bruker Corporation (Nasdaq: BRKR) announced today it will participate in the 2021 Wells Fargo Virtual Healthcare Conference. Gerald Herman, Executive Vice President & Chief Financial Officer, and Falko Busse, President of the Bruker BioSpin Group, will participate in an analyst moderated question and answer session on behalf of the Company on Friday, September 10, 2021 at 9:20 AM Eastern Time. A live audio webcast of the question and answer session will be

News for Bruker Stock (BRKR)